Amneal Pharmaceuticals, Inc. AMRX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s current debt?
- Amneal Pharmaceuticals, Inc. (AMRX) reported current debt of $6.2M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s current debt changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s current debt decreased by 80.5% year-over-year, from $31.79M to $6.2M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s current debt?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s current debt has grown at a -31.3% compound annual growth rate (CAGR), from $44.23M to $6.76M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.